Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma (TRAVELL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02247544|
Recruitment Status : Completed
First Posted : September 25, 2014
Last Update Posted : May 10, 2019
This is an Italian, multicentre, single arm, phase II study, with an intra-patient comparison end point. This study aims at confirming the activity of the drug trabectedin as second/further line treatment in retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma expressed in terms of slowing down tumour growth.
Another objective is to investigate this peculiar benefit of trabectedin in typical retroperitoneal sarcomas may be exploited to help multidisciplinary clinical decision-making in the management of retroperitoneal sarcomas
|Condition or disease||Intervention/treatment||Phase|
|Liposarcoma Leiomyosarcoma||Drug: Trabectedin||Phase 2|
Retroperitoneal soft-tissue sarcomas (R-STSs) are rare neoplasms, accounting for 10% to 15% of Soft Tissue Sarcomas (STSs), which represent 1-3% of all cancers. They may show different histological types, but the predominant ones in the retroperitoneal region are: leiomyosarcoma, liposarcoma. The most commonly encountered in the retroperitoneum is the well differentiated/dedifferentiated liposarcoma.
First-line chemotherapy usually consists of doxorubicin and/or ifosfamide. These two drugs are the most active agents in adult STSs, with a dose-response relationship and response rates between 20% and 50%. However, the sarcoma community is currently doubtful as to the activity of ifosfamide in the subgroup of leiomyosarcomas.
Trabectedin has been found to be mainly active in leiomyosarcoma and liposarcoma and is approved by European Medicines Agency (EMA) as second-line chemotherapy for STSs. Although the response rate observed in pre-registration studies did not exceed 10%, trabectedin provided disease control, with progression arrest rates exceeding 50% and Progression Free Survival (PFS) rates exceeding 20% at 6 months.
Since so far no phase II studies tested the activity of trabectedin in retroperitoneal sarcomas, this is the specific aim of this study.
Target population: Patients with previously treated, histologically confirmed, retroperitoneal leiomyosarcoma and well differentiated/dedifferentiated liposarcoma. Patients may be either unamenable to surgery or amenable but in whom the addition of medical treatment is considered clinically advisable.
Translational studies will be performed, with the aim of characterising the tumour biological features associated with different response patterns to trabectedin. These assessments will be done in 15-20 patients who will undergo surgery after trabectedin, comparing tumour tissue specimens collected before and after treatment.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||105 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Study on Trabectedin in Advanced Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma|
|Study Start Date :||March 2014|
|Actual Primary Completion Date :||March 12, 2019|
|Actual Study Completion Date :||March 12, 2019|
Trabectedin will be administered intravenously at a dose of 1.5 mg/m2 or 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour infusion once every 3 weeks (cycle day 1).
Since trabectedin has no cumulative toxicities, treatment can be continued until progressive disease, major toxicity, patient's intolerance or unwillingness to continue treatment or medical decision by the responsible physician. In the subgroup of patients amenable to surgery, treatment will be reasonably continued until the best dimensional response.
Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
Other Name: Yondelis
- Growth Modulation Rate [ Time Frame: From date of randomization until progressive disease, assessed up to 48 months ]The primary end point of the study will be the proportion of responders to trabectedin, based on the ratio, in each single patient, between PFS under trabectedin (PFS) and time to progression after previous chemotherapy treatment (TTP1).
- Objective response (OR) in the overall sample [ Time Frame: From date of randomization until progressive disease, assessed up to 48 months ]
- Pathological tumour response in the two eligible histological types, in patients undergoing surgery after treatment [ Time Frame: From date of randomization until the best tumour dimensional response, assessed up to 48 months ]
- PFS and OR in the two eligible histological types [ Time Frame: From date of randomization until progressive disease, assessed up to 48 months ]
- PFS in patients who undergo surgery after, or during, medical therapy and those who do not [ Time Frame: From date of randomization until progressive disease, assessed up to 48 months ]
- Number of patients with grade>=3 adverse drug reactions, number of serious adverse events related to study drug and number of patients who will experience at least one serious adverse event [ Time Frame: From date of randomization until progressive disease, assessed up to 48 months ]
- Efficacy of trabectedin in reducing cancer related pain [ Time Frame: From date of randomization until progressive disease, assessed up to 48 months ]All patients will be administered a standardized questionnaire evaluating cancer related pain and use of antalgic medication.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02247544
|Istituto Tumori Giovanni Paolo II|
|Bari, BA, Italy, 70124|
|Azienda Ospedaliera Giovanni Paolo XXIII|
|Bergamo, BG, Italy, 24127|
|Azienda Ospedaliera S. Orsola-Malpighi|
|Bologna, BO, Italy, 40138|
|A.O. Spedali Civili|
|Brescia, BS, Italy, 25123|
|Ospedale Oncologico A. Businco|
|Cagliari, CA, Italy, 09122|
|Azienda Ospedaliera S Croce e Carle|
|Cuneo, CN, Italy, 12100|
|Azienda Ospedaliera Sant'Anna|
|Como, CO, Italy, 22020|
|IRST IRCCS Meldola|
|Meldola, FC, Italy, 47014|
|Fondazione IRCCS Istituto Nazionale dei Tumori|
|Milano, MI, Italy, 20133|
|Istituto Europeo di Oncologia|
|Milano, MI, Italy, 20141|
|Istituto Clinico Humanitas|
|Rozzano, MI, Italy, 20089|
|Azienda Ospedaliera Universitaria Paolo Giaccone|
|Palermo, PA, Italy, 90127|
|Centro di Riferimento Oncologico di Aviano|
|Aviano, PD, Italy, 33081|
|Istituto Oncologico Veneto|
|Padova, PD, Italy, 35128|
|Azienda Ospedaliera Universitaria Santa Chiara|
|Pisa, PI, Italy, 56124|
|Ospedale Misericordia e Dolce|
|Prato, PO, Italy, 59100|
|Policlinico Universitario Campus Biomedico|
|Roma, RM, Italy, 00128|
|Istituto per la Ricerca e la Cura del Cancro di Candiolo|
|Candiolo, TO, Italy, 10060|
|Torino, TO, Italy, 10153|
|Azienda Ospedaliera Santa Maria|
|Terni, TR, Italy, 05100|
|Istituto Nazionale Tumori - IRCCS - Fondazione Pascale|
|Napoli, Italy, 80131|
|Principal Investigator:||Paolo G. Casali, MD||IRCCS Fondazione Istituto Nazionale per la cura dei tumori di Milano|